Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL.

Influenza Other Respir Viruses. 2013 Sep;7(5):815-26. doi: 10.1111/irv.12031. Epub 2012 Nov 5.


A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.

Deng J, Cai W, Jin F.

Int J Pharm. 2014 Jul 1;468(1-2):187-95. doi: 10.1016/j.ijpharm.2014.04.003. Epub 2014 Apr 4.


Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Rasid O, Vlase E, Coman C, Caras I, Ghiorghisor A, Berbecila L, Tofan V, Bowen RA, Marlenee N, Hartwig A, Bielefeldt-Ohmann H, Baldwin SL, Van Hoeven N, Vedvick TS, Huynh C, O'Hara MK, Noah DL, Fox CB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.


A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.

Chada KE, Forshee R, Golding H, Anderson S, Yang H.

Vaccine. 2017 May 31;35(24):3162-3170. doi: 10.1016/j.vaccine.2017.04.029. Epub 2017 May 5. Review.


GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.

Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG.

PLoS One. 2014 Feb 14;9(2):e88979. doi: 10.1371/journal.pone.0088979. eCollection 2014.


Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.

Treanor JJ, Chu L, Essink B, Muse D, El Sahly HM, Izikson R, Goldenthal KL, Patriarca P, Dunkle LM.

Vaccine. 2017 Feb 7;35(6):923-928. doi: 10.1016/j.vaccine.2016.12.053. Epub 2017 Jan 11.


An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.

Lau YF, Tang LH, McCall AW, Ooi EE, Subbarao K.

J Virol. 2010 Sep;84(17):8639-49. doi: 10.1128/JVI.00596-10. Epub 2010 Jun 10.


AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.

Klucker MF, Dalençon F, Probeck P, Haensler J.

J Pharm Sci. 2012 Dec;101(12):4490-500. doi: 10.1002/jps.23311. Epub 2012 Aug 31.


Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.


Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.


Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

Vaccine. 2011 Nov 28;29(51):9563-72. doi: 10.1016/j.vaccine.2011.08.089. Epub 2011 Sep 9.


An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.

J Infect Dis. 2008 Sep 1;198(5):642-9. doi: 10.1086/590913.


Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ.

Influenza Other Respir Viruses. 2011 Nov;5(6):426-37. doi: 10.1111/j.1750-2659.2011.00256.x. Epub 2011 May 9.


Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.

Howard LM, Hoek KL, Goll JB, Samir P, Galassie A, Allos TM, Niu X, Gordy LE, Creech CB, Prasad N, Jensen TL, Hill H, Levy SE, Joyce S, Link AJ, Edwards KM.

PLoS One. 2017 Jan 18;12(1):e0167488. doi: 10.1371/journal.pone.0167488. eCollection 2017.


Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade virus challenge in ferrets.

Sun X, Belser JA, Pulit-Penaloza JA, Creager HM, Guo Z, Jefferson SN, Liu F, York IA, Stevens J, Maines TR, Jernigan DB, Katz JM, Levine MZ, Tumpey TM.

Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26.


Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.

Ahmed SS, Schur PH, MacDonald NE, Steinman L.

J Autoimmun. 2014 May;50:1-11. doi: 10.1016/j.jaut.2014.01.033. Epub 2014 Feb 19. Review.


Adjuvant solution for pandemic influenza vaccine production.

Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, Bowen RA, Reed SG.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17585-90. doi: 10.1073/pnas.1207308109. Epub 2012 Oct 8.


Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.


The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance.

Shah RR, Dodd S, Schaefer M, Ugozzoli M, Singh M, Otten GR, Amiji MM, O'Hagan DT, Brito LA.

J Pharm Sci. 2015 Apr;104(4):1352-61. doi: 10.1002/jps.24337. Epub 2015 Jan 19.


Supplemental Content

Support Center